<?xml version="1.0" encoding="UTF-8"?>
<p>The ongoing EVAPORATE trial [
 <xref rid="B101-nutrients-12-03782" ref-type="bibr">101</xref>], where 4 g/d of pure EPA was administered to cardiovascular patients with triglyceride concentrations 200 to 499 mg/dL, just reported significant regression of low-attenuation plaque volume measured by serial multidetector computed tomography [
 <xref rid="B90-nutrients-12-03782" ref-type="bibr">90</xref>,
 <xref rid="B102-nutrients-12-03782" ref-type="bibr">102</xref>] and helped shed some light on the dose issue [
 <xref rid="B103-nutrients-12-03782" ref-type="bibr">103</xref>].
</p>
